Candel Therapeutics (CADL) Stock Fair Value Moves Lower After Analysts Cut Targets
HC Wainwright & Co. Maintains Buy on Candel Therapeutics, Lowers Price Target to $18
Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
Canaccord Genuity Maintains Buy on Candel Therapeutics, Lowers Price Target to $13
Stifel Maintains Buy on Candel Therapeutics, Lowers Price Target to $19
Candel Therapeutics Shares Tumble 39% After-Hours: Here's Why
CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics Q3 EPS $(0.28) Beats $(0.35) Estimate
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting
Candel Therapeutics to Present at November Investor Conferences
Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.